Visual N80 latency as a marker of neuropsychological performance in schizophrenia: Evidence for bottom-up cognitive models.


Journal

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
ISSN: 1872-8952
Titre abrégé: Clin Neurophysiol
Pays: Netherlands
ID NLM: 100883319

Informations de publication

Date de publication:
04 2021
Historique:
received: 11 08 2020
revised: 14 12 2020
accepted: 05 01 2021
pubmed: 27 2 2021
medline: 28 8 2021
entrez: 26 2 2021
Statut: ppublish

Résumé

Cognitive deficits and visual impairment in the magnocellular (M) pathway, have been independently reported in schizophrenia. The current study examined the association between neuropsychological (NPS) performance and visual evoked potentials (VEPs: N80/P1 to M- and P(parvocellular)-biased visual stimuli) in schizophrenia and healthy controls. NPS performance and VEPs were measured in n = 44 patients and n = 34 matched controls. Standardized NPS-scores were combined into Domains and a PCA (Principal Component Analysis) generated Composite. Group differences were assessed via (M)ANOVAs, association between NPS and VEP parameters via PCA, Pearson's coefficient and bootstrapping. Logistic regression was employed to assess classification power. Patients showed general cognitive impairment, whereas group differences for VEP-parameters were non-significant. In patients, N80 latency across conditions loaded onto one factor with cognitive composite, showed significant negative correlations of medium effect sizes with NPS performance for M/P mixed stimuli and classified low and high performance with 70% accuracy. The study provides no evidence for early visual pathway impairment but suggests a heightened association between early visual processing and cognitive performance in schizophrenia. Our results lend support to bottom-up models of cognitive function in schizophrenia and implicate visual N80 latency as a potential biomarker of cognitive deficits in schizophrenia.

Identifiants

pubmed: 33636604
pii: S1388-2457(21)00022-5
doi: 10.1016/j.clinph.2021.01.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

872-885

Informations de copyright

Copyright © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest MW and SA were involved in the development of neuropsychological diagnostic and training tools with Schuhfried GmbH (Mödling, Austria). All authors declare no competing interests.

Auteurs

Felix Hever (F)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany. Electronic address: felix.hever@erasme.ulb.ac.be.

Derya Sahin (D)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany.

Steffen Aschenbrenner (S)

Department of Psychiatry and Psychotherapy, SRH Hospital Karlsbad-Langensteinbach, Germany.

Magdalena Bossert (M)

Department of Psychiatry and Psychotherapy, SRH Hospital Karlsbad-Langensteinbach, Germany.

Kerstin Herwig (K)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany.

Gustav Wirtz (G)

SRH RPK Karlsbad, Psychiatric Rehabilitation, Karlsbad-Langensteinbach, Germany.

Rieke Oelkers-Ax (R)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany.

Matthias Weisbrod (M)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany; Department of Psychiatry and Psychotherapy, SRH Hospital Karlsbad-Langensteinbach, Germany.

Anuradha Sharma (A)

Research Group Neurocognition, Department of General Psychiatry, Centre for Psychosocial Medicine, Heidelberg University, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH